Patents
US 12104163 B2: Adeno-associated virus vectors for treatment of Rett syndrome
- Granted
- 2024-10-01
- Filed
- 2021-08-19 application 17406723
- Type
- Utility · 27 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The disclosure provides nucleic acids (comprising AAV expression cassettes), AAV vectors, and compositions for use in methods for treating and/or delaying the onset of diseases associated with mutations in the mecp2 gene, such as Rett Syndrome. Also, provided herein are methods for treating and/or delaying the onset of brain-derived neurotrophic factor (BDNF)-associated diseases.
Source: PVGPATDIS, file of 2026-04-10 (ipg241001.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Colin O'Banion | Durham, NC | 1 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/86 | PVGPATDIS, file of 2026-04-10 |
| A61K | Preparations for medical, dental or toiletry purposes | A61K38/185 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P25/28 | PVGPATDIS, file of 2026-04-10 |
| C07K | Peptides | C07K14/4702 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
| 2023-02-07 | Assignment Assignment of assignor's interest | STRIDEBIO, INC. signed 2023-01-18 | SAREPTA THERAPEUTICS, INC. CAMBRIDGE, MA | 62608/243 | PASDL, file of 2026-10-15 |
| 2023-01-19 | Assignment Assignment of assignor's interest | O'BANION, COLIN signed 2023-01-17 | STRIDEBIO, INC. RESEARCH TRIANGLE, NC | 62418/429 | PASDL, file of 2026-10-15 |
| 2022-01-06 | Assignment Assignment of assignor's interest | O'BANION, COLIN signed 2020-12-11 | STRIDEBIO, INC. RESEARCH TRIANGLE, NC | 58585/828 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.